Article | November 12, 2015

Considerations To Ensure Successful Scale-up Of Single-use Processes

use automation from laboratory-scale to large-scale production

By Donald Beers

The increasing distance between new molecular entities output and pharmaceutical spending is often referred to as the Innovation Gap. Donald Beers examines the single-use explanation for this and reveals the considerations to ensure successful implementation of single-use automation from laboratory-scale to large-scale production

Recent trends in the biopharmaceutical market have shown a reduction in the number of large companies which are spending their entire R & D budget on developing new drugs1. Instead, start-up biotech companies are the major source of innovation within the biopharm industry and of new molecular entities (NMEs). The main goal of these start-ups with new products or interesting therapeutics is to survive. Survival in this case means getting far enough into the Food and Drug Administration (FDA) approval process to be bought or licensed by a large company.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: